Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.

ABSTRACT:

Background

Imeglimin is a first-in-class novel oral antidiabetic marketed in Japan as TWYMEEG^® to treat type 2 diabetes mellitus. Its mode of action is distinct from all other anti-hyperglycemic classes.

Objective

To assess the pharmacokinetic and safety profile of imeglimin in Caucasian and Japanese healthy individuals.

Methods

Two randomized placebo-controlled phase 1 clinical studies were conducted in Caucasian subjects after single (250-8000 mg) and multiple (250-2000 mg twice daily) ascending doses and in Japanese subjects after single (500-6000 mg) and multiple (500-2000 mg twice daily) ascending doses. Imeglimin plasma and urine concentrations were measured.

Results

All imeglimin doses achieved maximal concentration between 1 and 3.5 h in Cauc

SUBMITTER: Fouqueray P 

PROVIDER: S-EPMC9427879 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature